Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-05-27 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于持股5%以上股东集中竞价减持股份时间过半的进展公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a shareholder's share reduction plan, specifically a shareholder holding more than 5% of shares reducing their holdings through centralized bidding. It details the number of shares held before and after reduction, the reduction period, prices, and the impact on company control. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a major shareholder's transaction activity, fitting the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or earnings release.
2022-05-27 Chinese
圣湘生物科技股份有限公司2021年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Implementation Announcement" for the 2021 annual equity distribution by 圣湘生物科技股份有限公司. It details the dividend distribution, share transfer ratios, relevant dates, tax implications, and share capital changes. The document is an announcement of the dividend and share capital increase plan approved at the 2021 annual shareholders meeting. It includes specific dividend amounts, record dates, ex-dividend dates, and implementation methods. The document length is 3931 characters, which is relatively short and consistent with an announcement rather than a full report. It does not contain comprehensive financial statements or detailed financial analysis, but rather focuses on the dividend distribution details and related shareholder information. Therefore, this document fits the category of "Notice of Dividend Amount" (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2022-05-25 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司差异化分红事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion issued by a sponsoring securities firm regarding a differentiated dividend distribution matter of a listed company. It discusses the legal compliance and calculation basis of the dividend distribution related to share repurchases. The document is not a full financial report, earnings release, or management discussion, but rather a formal opinion or verification statement related to a specific corporate action (differentiated dividend). It does not contain comprehensive financial statements or detailed financial analysis. The document length is relatively short (2493 characters), and it is a formal verification opinion rather than a report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance documents that do not fit other specific categories.
2022-05-25 Chinese
圣湘生物科技股份有限公司关于自愿披露全资子公司相关检测产品获得欧盟CE List A认证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 圣湘生物科技股份有限公司 regarding the voluntary disclosure that its wholly-owned subsidiary has obtained the EU CE List A certification for certain nucleic acid test kits. The text includes details about the certification, product description, potential market impact, and risk warnings. It is a regulatory announcement informing investors and the public about a significant product certification event and its implications. The document is relatively short (2153 characters) and does not contain financial statements, detailed financial analysis, or management discussion of financial results. It is not an annual or interim report, earnings release, or any form of financial report. It is also not a meeting material, voting result, or insider transaction. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a product certification and its business impact, which does not fit into more specific categories like capital update or legal proceedings. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2022-05-24 Chinese
圣湘生物科技股份有限公司关于自愿披露公司相关检测产品获得欧盟CE List A认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of the company's products obtaining EU CE List A certification. It details product registration information, the impact on the company, and risk warnings. There are no financial statements, no mention of quarterly or annual results, no management discussion of financial performance, and no regulatory filings or certifications. The document is an announcement about a product certification event, not a financial report or management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is a regulatory announcement informing investors about a significant product certification and its potential impact, which aligns best with Regulatory Filings (RNS). The document length is short (2314 characters), and it is not a report publication announcement or certification letter. Therefore, the best classification is Regulatory Filings (RNS).
2022-05-22 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It details the product registration information, its intended use, and the potential impact on the company. There is no financial data, no mention of a report being attached or published, and no regulatory certification or officer attestation. The document is an official announcement about a product registration, which fits best under general regulatory announcements that do not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short (996 characters), and it is not a report or a report publication announcement.
2022-05-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.